Advances in human papilloma virus vaccines: A patent review

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 3, 2011, Pages 295-309

  Cho, Hee Jeong ^a   Oh, Yu Kyoung ^a   Kim, Young Bong ^b,c  

^a Seoul National University   (South Korea)

^b Konkuk University   (South Korea)

^c KR Biotech Co   (South Korea)

Author keywords

adjuvant system; cervical cancer; DNA vaccine; HPV; human papilloma virus; prophylactic vaccine; therapeutic vaccine

Indexed keywords

3 DEACYLATED MONOPHOSPHORYL LIPID A; ADENOVIRUS VECTOR; AMOLIMOGENE; AMOLIMOGENE BEPIPLASMID; BACULOVIRUS VECTOR; CALNEXIN; CALRETICULIN; CAPSID PROTEIN L1; CHOLERA TOXIN B SUBUNIT; DNA VACCINE; EDIBLE VACCINE; HEAT SHOCK PROTEIN 100; HEAT SHOCK PROTEIN 110; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HYALURONIC ACID; IOXAGLIC ACID; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; PHOSPHORYL LIPID A; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN E5; PROTEIN E6; PROTEIN E7; PROTEIN L1; PROTEIN L2; TAPASIN; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS PROTEIN; WART VIRUS VACCINE;

ADENOVIRUS 5; ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CONDYLOMA ACUMINATUM; DRUG COST; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MANUFACTURE; GENE GUN IMMUNIZATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNIZATION; IMMUNOGENICITY; LACTIC ACID BACTERIUM; NONHUMAN; REVIEW; SEMLIKI FOREST ALPHAVIRUS; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINE PRODUCTION; VIRUS LIKE AGENT;

ADJUVANTS, IMMUNOLOGIC; CAPSID PROTEINS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS VACCINES; PATENTS AS TOPIC; RECOMBINANT FUSION PROTEINS; TOLL-LIKE RECEPTORS; VACCINES, DNA; VACCINES, SYNTHETIC; VIRION;

EID: 79952060998     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2011.551114     Document Type: Review

References (136)

1. DAndrilli G, Bovicelli A, Giordano A. HPV vaccines: state of the art. J Cell Physiol 2010;224(3):601-4
2. Bermudez-Humaran LG, Langella P. Perspectives for the development of human papillomavirus vaccines and immunotherapy. Expert Rev Vaccines 2010;9(1):35-44
3. Munoz N, Bosch FX, de Sanjose S, et al International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;21(6):518-27 (Pubitemid 36159887)
4. Harper DM. Currently approved prophylactic HPV vaccines. Expert Rev Vaccines 2009;8(12):1663-79
5. Stanley MA. Human papillomavirus vaccines. Rev Med Virol 2006;16(3):139-49 (Pubitemid 43864963)
6. McNeil C. Who invented the VLP cervical cancer vaccines? J Natl Cancer Inst 2006;98:433
7. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991;185(1):251-7
8. Ghim SJ, Jenson AB, Schlegel R. HPV-1 L1 protein expressed in cos cells displays conformational epitopes found on intact virions. Virology 1992;190(1):548-52
9. Kirnbauer R, Booy F, Cheng N, et al Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992;89(24):12180-4 (Pubitemid 23004809)
10. Rose RC, Bonnez W, Reichman RC, Garcea RL. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol 1993;67(4):1936-44 (Pubitemid 23088366)
11. Padmanabhan S, Amin T, Sampat B, et al Intellectual property, technology transfer and manufacture of low-cost HPV vaccines in India. Nat Biotechnol 2010;28(7):671-8
12. GlaxoSmithkline, Biolog SA. HPV-16 and -18 L1 VLP vaccine. WO2004056389; 2004
13. GlaxoSmithkline, Biolog SA. Vaccine against HPV 16 and HPV 18 and at least another HPV types selected from 31, 45 or 52. WO2005123125; 2005
14. GlaxoSmithkline, Biolog SA. Vaccine. WO2006114312; 2006
15. Merck & Co., Inc. Optimized expression of HPV 31 L1 in yeast. WO200408483; 2004
16. Merck & Co., Inc. Optimized expression of HPV 45 L1 in yeast. WO2005032586; 2005
17. Merck & Co., Inc. Optimized expression of HPV 52 L1 in yeast. WO2005097821; 2005
18. Merck & Co., Inc. Optimized expression of HPV 58 L1 in yeast. WO2005047315; 2005
19. Indian Immunologicals Ltd. Codon-optimized HPV16 L1 for salmonella vaccine strains against human papillomavirus type 16. WO2005123762; 2005
20. Univ Konkuk Ind. Coop. Corp. Baculovirus-based vaccines. WO2009088256; 2009
21. Univ Cape Town. Chimeric human papillomavirus 16 L1 proteins comprising an L2 peptide,virus-like particles prepared therefrom and a method for preparing the particles. EP1506222; 2009
22. Loyola University Chicago. Papilloma virus capsomere vaccine formulations and methods of use. US7754430; 2010
23. Shi L, Sings HL, Bryan JT, et al GARDASIL: prophylactic human papillomavirus vaccine development-from bench top to bed-side. Clin Pharmacol Ther 2007;81:259-64 (Pubitemid 46174823)
24. GlaxoSmithKline Vaccine HPV-007 Study Group, Romanowski B, de Borba PC, et al Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009;374(9706):1975-85
25. Brandsma JL, Shylankevich M, Su Y, et al Vesicular stomatitis virus-based therapeutic vaccination targeted to the E1, E2, E6, and E7 proteins of cottontail rabbit papillomavirus. J Virol 2007;81(11):5749-58 (Pubitemid 46847013)
26. Monie A, Tsen SW, Hung CF, Wu TC. Therapeutic HPV DNA vaccines. Expert Rev Vaccines 2009;8(9):1221-35
27. Wu CY, Monie A, Pang X, et al Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation. J Biomed Sci 2010;17(1):88
28. Li M, Cripe TP, Estes PA, et al Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly. J Virol 1997;71(4):2988-95 (Pubitemid 27119942)
29. Senger T, Schadlich L, Gissmann L, Muller M. Enhanced papillomavirus-like particle production in insect cells. Virology 2009;388(2):344-53
30. Hagensee ME, Yaegashi N, Galloway DA. Self-assembly of human papillomavirus type 1 capsids by expression of L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 1993;67:315-22 (Pubitemid 23002992)
31. Hofmann KJ, Neeper NP, Markus HZ, et al Sequence conservation within the major capsid protein of human papillomavirus (HPV) type 18 and formation of HPV-18 viruslike particles in Saccharomyces cerevisiae. J Gen Virol 1996;77:465-8 (Pubitemid 26073352)
32. Neeper MP, Hofmann KH, Jansen KU. Expression of the major capsid protein of human papillomavirus type 11 in Saccharomyces cerevisiae. Gene 1996;180:1-6 (Pubitemid 26417901)
33. Giorgi C, Franconi R, Rybicki EP. Human papillomavirus vaccines in plants. Expert Rev Vaccines 2010;9:913-24
34. Waheed MT, Thones N, Muller M, et al Transplastomic expression of a modified human papillomavirus L1 protein leading to the assembly of capsomeres in tobacco: a step towards cost-effective second-generation vaccines. Transgenic Res 2010. [Epub ahead of print]
35. Demain AL, Vaishnav P. Production of recombinant proteins by microbes and higher organisms. Biotechnol Adv 2009;27(3):297-306
36. Hatfield GW, Roth DA. Optimizing scaleup yield for protein production: computationally Optimized DNA Assembly (CODA) and translation engineering. Biotechnol Annu Rev 2007;13:27-42 (Pubitemid 47387122)
37. McNulty DE, Claffee BA, Huddleston MJ, et al Mistranslational errors associated with the rare arginine codon CGG in Escherichia coli. Protein Expr Purif 2003;27:365-74 (Pubitemid 36339309)
38. Sorensen HP, Mortensen KK, Advanced genetic strategies for recombinant protein expression in Escherichia coli. J Biotechnol 2005;115:113-28 (Pubitemid 39656438)
39. Mossadegh N, Gissmann L, Muller M, et al Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells. Virology 2004;326(1):57-66 (Pubitemid 38943006)
40. Maclean J, Koekemoer M, Olivier AJ, et al Optimization of human papillomavirus type 16 (HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization. J Gen Virol 2007;88:1460-9 (Pubitemid 46723227)
41. Carter JJ, Yaegashi N, Jenison SA, Galloway DA. Expression of human papillomavirus proteins in yeast Saccharomyces cerevisiae. Virology 1991;182(2):513-21
42. Park DS, Selvey LA, Kelsall SR, Frazer IH. Human papillomavirus type 16 E6, E7 and L1 and type 18 E7 proteins produced by recombinant baculoviruses. J Virol Methods 1993;45(3):303-18
43. Reinstein E, Scheffner M, Oren M, et al Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue. Oncogene 2000;19(51):5944-50 (Pubitemid 32005376)
44. Csl Ltd. Papillomavirus polyprotein constructs. US6365160; 2002
45. Enea Ente Nuove Tec. Subunit vaccines and processes for the production thereof. EP1401493; 2007
46. Kadish AS, Einstein MH. Vaccine strategies for human papillomavirus- associated cancers. Curr Opin Oncol 2005;17(5):456-61 (Pubitemid 41224926)
47. Kawana K, Yasugi T, Taketani Y. Human papillomavirus vaccines: current issues & future. Indian J Med Res 2009;130(3):341-7
48. MediGene AG. Papillomavirus truncated L1 protein and fusion protein constructs. US6649167; 2003
49. Lin CT, Chang TC, Chao A, et al Enhancement of DNA vaccine potency through linkage of antigen gene to ER chaperone molecules, ER-60, tapasin, and calnexin. J Biomed Sci 2005;12(2):279-87 (Pubitemid 40903111)
50. Sunbio Biotech Pharmaceuticals, HPV antigen fusion protein vaccine compositions and uses thereof. WO2008049329; 2008
51. GlaxoSmithkline, Biolog SA. Vaccine against HPV. EP1007551; 2004
52. Christensen ND, Reed CA, Cladel NM, et al Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV 11 in addition to typespecific epitopes on HPV-6. Virology 1996;224:477-86 (Pubitemid 26364495)
53. White WI, Wilson SD, Bonnez W, et al In vitro infection oftype-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J Virol 1998;72:959-64
54. GlaxoSmithKline Biologicals SA. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52. WO2005123125; 2005
55. Smithkline Beecham Corp. Vaccine against HPV. WO2008145745; 2008
56. Novartis Vaccines and Diagnostics, Inc. Method for producing yeast expressed HPV types 6 and 16 capsid proteins. US7494787; 2009
57. Sasagawa T, Pushko P, Steers G, et al Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology 1995;206(1):126-35
58. Johns Hopkins University. Papillomavirus L2 N-terminal peptides for the induction of broadly cross-neutralizing antibodies. US20090047301; 2009
59. Jagu S, Karanam B, Gambhira R, et al Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst 2009;101:782-92
60. GlaxoSmithKline Biologicals SA. Novel composition. WO2002087614; 2002
61. GlaxoSmithKline Biologicals SA. Vaccine composition comprising herpes simplex virus and human papilloma virus antigens. US6936255; 2005
62. GlaxoSmithKline Biologicals SA. Vaccine against hbv and hpv. EP1731167; 2008
63. Smithkline Beecham Biolog. Vaccine against HBV and HPV. US7371390; 2008
64. Wheeler CM, Bautista OM, Tomassini JE, et al Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 2008;26(5):686-96
65. Warzecha H, Mason HS, Lane C, et al Oral immunogenicity of human papillomaviruslike particles expressed in potato. J Virol 2003;77:8702-11 (Pubitemid 36936081)
66. Biemelt S, Sonnewald U, Galmbacher P, et al Production of human papillomavirus type 16 virus-like particles in transgenic plants. J Virol 2003;77(17):9211-20 (Pubitemid 37011018)
67. Cho HJ, Shin HJ, Han IK, et al Induction of mucosal and systemic immune responses following oral immunization of mice with Lactococcus lactis expressing human papillomavirus type 16 L1. Vaccine 2007;25(47):8049-57
68. Asahi Glass Co. Ltd. Edible vaccine. US20090017063; 2009
69. Asahi Glass Co. Ltd. Edible vaccine. Human papilloma virus vaccine for oral administration. EP1790332; 2010
70. Sasagawa T, Tani M, Basha W, et al A human papillomavirus type 16 vaccine by oral delivery of L1 protein. Virus Res 2005;110(1-2):81-90 (Pubitemid 40544549)
71. Bioleaders Corp. Vector for treatment vaccine for stable and constitutive high-expression cervical cancer and recombinant Lactobacillus transformed by the same. WO2010079991; 2010
72. Genomine, Inc. Recombinant human papillomavirus vaccine expressed in transgenic plants. US6444805; 2002
73. Varmus H, Klausner R, Zerhouni E, et al Public health grand challenges in grobal health. Science 2003;302:398-99 (Pubitemid 37296252)
74. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol 2008;26(11):1261-8
75. Mitragotri S. Immunization without needles. Nat Rev Immunol 2005;5:905-16 (Pubitemid 41746760)
76. Felotn medical, Inc. Disposable unit-dose jet-injection syringe for pre-filled and/or transfilled liquid injectable medical drug or vaccine products and method thereof. US6610042; 2003
77. Han R, Peng XW, Reed CA, et al Gene gun-mediated intracutaneous vaccination with papillomavirus E7 gene delays cancer development of papillomavirus-induced skin papillomas on rabbits. Cancer Detect Prev 2002;26:458-67 (Pubitemid 36035376)
78. Matthews K, Rhind SM, Gossner AG, et al The effect of gene gun-delivered pGM-CSF on the mmunopathology of the vaccinated skin. Scand J Immunol 2007;65(3):298-307
79. Bioware Technology Co. Ltd. Low pressure gas accelerated gene gun. US7638332; 2009
80. Sivamani RK, Liepmann D, Maibach HI. Microneedles and transdermal applications. Expert Opin Drug Deliv 2007;4(1):19-25 (Pubitemid 46117483)
81. Matriano JA, Cormier M, Johnson J, et al Macroflux microprojection array patch technology: a new and efficient approach for intracutaneous immunization. Pharm Res 2002;19(1):63-70 (Pubitemid 34075108)
82. De Magistris MT. Mucosal delivery of vaccine antigens and its advantages in pediatrics. Adv Drug Deliv Rev 2006;58(1):52-67
83. Lavelle EC. Generation of improved mucosal vaccines by induction of innate immunity. Cell Mol Life Sci 2005;62(23):2750-70 (Pubitemid 41779945)
84. Singh M, Briones M, OHagan DT. A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. J Control Release 2001;70(3):267-76 (Pubitemid 32155450)
85. Chiron Corp. Use of hyaluronic acid polymers for mucosal delivery of vaccine and adjuvants. US6824793; 2004
86. Han IK, Kim YB, Kang HS, et al Thermosensitive and mucoadhesive delivery systems of mucosal vaccines. Methods 2006;38(2):106-11 (Pubitemid 43163470)
87. Park JS, Oh YK, Kang MJ, et al Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems. J Med Virol 2003;70(4):633-41
88. Cho HJ, Kim JY, Lee Y, et al Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants. Vaccine 2010;28(14):2598-606
89. Shahiwala A, Vyas TK, Amiji MM. Nanocarriers for systemic and mucosal vaccine delivery. Recent Pat Drug Deliv Formul 2007;1(1):1-9
90. Chadwick S, Kriegel C, Amiji M. Delivery strategies to enhance mucosal vaccination. Expert Opin Biol Ther 2009;9(4):427-40
91. Chadwick S, Kriegel C, Amiji M. Nanotechnology solutions for mucosal immunization. Adv Drug Deliv Rev 2010;62(4-5):394-407
92. Garg NK, Mangal S, Khambete H, et al Mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymers. Recent Pat Drug Deliv Formul 2010;4(2):114-28
93. Novartis vaccines & Diagnostic. Non-toxic mucosal adjuvant. EP732937; 2009
94. Medeva Holdings BV. Vaccine compositions for mucosal delivery. EP937462; 2006
95. Austin Res Inst. Mannose as intranasal vaccine adjuvant. EP1301208; 2010
96. Lin K, Roosinovich E, Ma B, et al Therapeutic HPV DNA vaccines. Immunol Res 2010;47(1-3):86-112
97. Univ Johns Hopkins. Molecular vaccine linking an endoplasmic chaperone polypeptide to an antigen. US7342002; 2008
98. Howe C, Garstka M, Al-Balushi M, et al Calreticulin-dependent recycling in the early secretory pathway mediates optimal peptide loading of MHC class I molecules. EMBO J 2009;28(23):3730-44
99. Gold LI, Eggleton P, Sweetwyne MT, et al Calreticulin: non-endoplasmic reticulum functions in physiology and disease. FASEB J 2010;24(3):665-83
100. Univ Johns Hopkins. Anti-cancer DNA vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin. US20080102084; 2008
101. Univ Johns Hopkins. HPV DNA vaccines and methods of use thereof. US20080260765; 2008
102. Glaxo Group Ltd. DNA vaccine encoding at least two nonstructural early proteins of papillomavirus. EP1546191; 2005
103. Moore RA, Santos EB, Nicholls PK, et al Intraepithelial DNA immunization with a plasmid encoding a codon optimised COPV E1 gene sequence, but not the wild-type gene sequence completely protects against mucosal challenge with infectious COPV in beagles. Virology 2002;304(2):451-9 (Pubitemid 36069183)
104. Sungkyunkwan University Found. A DNA vaccine for treating or preventing cervical cancer comprising a gene encoding HPV protein. WO2008026869; 2008
105. Garcia F, Petry KU, Muderspach L, et al ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2004;103(2):317-26
106. A Study of Amolimogene (ZYC101a) in Patients with High Grade Cervical Intraepithelial Lesions of the Uterine Cervix. FDA Public Health Advisory. Washington, DC: FDA/Center for Drug Evaluation and Research, 2005. Available from:
107. Vaccine Therapy With or Without Imiquimod in Treating Patients WithGrade 3 Cervical Intraepithelial Neoplasia. FDA Public Health Advisory. Washington, DC: FDA/Center for Drug Evaluation and Research, 2008. Available from:
108. Gabitzsch ES, Xu Y, Yoshida LH, et al A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses. Immunol Lett 2009;122(1):44-51
109. Gabitzsch ES, Xu Y, Yoshida LH, et al Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity. Vaccine 2009;27(46):6394-8
110. Beth Israel Hospital. Adenoviral vectors and uses thereof. US7741099; 2010
111. Bangari DS, Mittal SK. Porcine adenoviral vectors evade preexisting humoral immunity to adenoviruses and efficiently infect both human and murine cells in culture. Virus Res 2004;105(2):127-36 (Pubitemid 39207935)
112. Peruzzi D, Dharmapuri S, Cirillo A, et al A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines. Vaccine 2009;27(9):1293-300
113. Osada T, Yang XY, Hartman ZC, et al Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity. Cancer Gene Ther 2009;16(9):673-82
114. Deisseroth Albert B. Adenoviral vector vaccine. EP1563074; 2005
115. Univ Pennsyvania. Simian subfamily C adenoviruses SADV-40, -31, and -34 and uses thereof. WO2009105084; 2009
116. Univ Groningen. Genetic immunization against cervical carcinoma. US7198792; 2007
117. Daemen T, Pries F, Bungener L, et al Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7. Gene Ther 2000;7(21):1859-66
118. GSF Forschungszentrum Umweltus. Modified vaccinia virus Ankara (MVA) mutant and use thereof. US7767209; 2010
119. Cadila Healthcare Ltd. Combined measles-human papilloma vaccine. WO2010079505; 2010
120. Cantarella G, Liniger M, Zuniga A, et al Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma. Vaccine 2009;27(25-26):3385-90
121. Lee HJ, Park N, Cho HJ, et al Development of a novel viral DNA vaccine against human papillomavirus: AcHERV-HP16L1. Vaccine 2010;28(6):1613-19
122. Univ Pennsylvania. Compositions and methods for enhancing the immunogenicity of antigens. US7588930; 2009
123. Gunn GR, Zubair A, Peters C, et al Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol 2001;167(11):6471-9 (Pubitemid 33081581)
124. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007;7(3):179-90
125. Ribi ImmunohemReserch, Inc. Aqueous immunogical adjuvant compositions of monophosphoryl lipid A. EP0971739; 2004
126. Corixa Corp. Aqueous immunogical adjuvant compositions of monophosphoryl lipid A. EP1194166; 2007
127. Smithkline Beecham Biolog. Adjuvnat systems and vaccines. US7357936; 2008
128. Ainai A, Ichinohe T, Tamura S, et al Zymosan enhances the mucosal adjuvant activity of poly(I:C) in a nasal influenza vaccine. J Med Virol 2010;82(3):476-84
129. Dobeel Co. Ltd. A powerful vaccine composition comprising a lipopeptide and poly I:C as an adjuvant. WO2009072767; 2009
130. Glaxo Group Ltd. Improvements in vaccination. WO2005025614; 2005
131. Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: an update review. Curr Drug Deliv 2007;4(4):297-305 (Pubitemid 47554274)
132. Klinguer C, Beck A, De-Lys P, et al Lipophilic quaternary ammonium salt acts as a mucosal adjuvant when co-administered by the nasal route with vaccine antigens. Vaccine 2001;19(30):4236-44 (Pubitemid 32703645)
133. Smithkline Beecham Biolog. Oil in water emulsions containing saponins. US7323182; 2008
134. Statens Seruminstitut. Modified cationic liposome adjuvant. WO2010054654; 2010
135. GlaxoSmithKline Biologicals S.A. The use of liposomes containing saponins and sterols in the manufacture of intradermal vaccines. EP1432442; 2007
136. Merck Sharpe & Dohme. Papillomavirus vaccine compositions. US7709010; 2010